Kyverna Therapeutics/$KYTX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Kyverna Therapeutics
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
- Ticker
- $KYTX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 149
- Headquarters
- Emeryville, United States
- Website
- kyvernatx.com
KYTX Metrics
BasicAdvanced
$311M
-
-$2.74
-
-
Price and volume
Market cap
$311M
52-week high
$13.67
52-week low
$4.50
Average daily volume
861K
Financial strength
Current ratio
7.012
Quick ratio
6.786
Long term debt to equity
0.234
Total debt to equity
0.244
Interest coverage (TTM)
-64.90%
Profitability
EBITDA (TTM)
-161.677
Management effectiveness
Return on assets (TTM)
-54.14%
Return on equity (TTM)
-110.69%
Valuation
Price to book
2.36
Price to tangible book (TTM)
2.36
Price to free cash flow (TTM)
-1.902
Free cash flow yield (TTM)
-52.58%
Free cash flow per share (TTM)
-2.645
Growth
Earnings per share change (TTM)
-26.40%
3-year earnings per share growth (CAGR)
-67.44%
What the Analysts think about KYTX
Analyst ratings (Buy, Hold, Sell) for Kyverna Therapeutics stock.
Analyst projections of the future price of Kyverna Therapeutics stock.
Bulls say / Bears say
In the 26-patient SPS trial, the median walking improvement was 49% at 12 months, and 95% of patients who had achieved a clinically meaningful improvement at the earlier analysis maintained it. This durability strengthens the case for a one-off treatment with lasting benefit. (U.S. Securities and Exchange Commission)
Early gMG results were encouraging: all treated patients achieved clinically meaningful reductions in disease scores, with responses sustained to 52 weeks in the three patients with that much follow-up. If confirmed in the ongoing Phase 3 trial, this could support a second major indication for miv-cel. (U.S. Securities and Exchange Commission)
Kyverna has started its rolling SPS biologics application, submitted the manufacturing module and signed a commercial supply agreement for miv-cel. These steps advance regulatory and manufacturing readiness ahead of its targeted 2027 launch, subject to approval. (U.S. Securities and Exchange Commission, U.S. Securities and Exchange Commission)
The SPS pivotal study was a single-arm trial of 26 patients, so its results are based on a small group without a concurrent control. The FDA may require further studies, leaving approval and timing uncertain. (Clinical Trial Vanguard, U.S. Securities and Exchange Commission)
The autoimmune CAR T class faces fresh safety scrutiny: Novartis and Bristol Myers paused trials after serious inflammatory events, including deaths in Novartis’s programme. Even if Kyverna’s treatment and manufacturing differ, heightened caution could weigh on regulatory review and investor confidence. (BioPharma Dive)
Kyverna had $199.4 million in cash and securities at the end of June 2026, but its first-half operating cash use was $81.9 million. Management’s funding outlook relies on available loans and an at-the-market share facility as well as cash, creating financing and potential dilution risk while the company remains loss-making. (StockTitan)
Data summarised monthly by Lightyear AI. Last updated on 17 Oct 2026.
KYTX Financial Performance
Revenues and expenses
KYTX Earnings Performance
Company profitability
Upcoming events
No upcoming events
KYTX News
AllArticlesVideos
Funds containing KYTX
Fund name | Fund size | $KYTX weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.3B | 0.02% |
iShares Nasdaq US Biotechnology$BTEC | $1.3B | 0.02% |
SPDR Russell 2000 US Small Cap€R2US | $4.7B | 0.01% |
SPDR Russell 2000 US Small Cap£R2SC | $4.7B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.